| Variable | SAKK trial 11 | USA phase II trial 20 | EORTC 08031 |
| Patients/institutions n/n | 61/6 | 77/9 | 59/11 |
| Induction regimen | Cis–gem ×3 | Cis–pem ×4 | Cis–pem ×3 |
| Compliance to induction chemotherapy | 95 | 83 | 93 |
| EPP | 45 (74) | 54 (70) | 42 (74) |
| Operative mortality | 2.2 | 7 | 6.5 |
| pCR rate | 2.2 | 5 | 4.8 |
| PORT completed | 36 (59) | 40 (52) | 37 (65) |
| OS months | |||
| ITT | 19.8 (14.6–24.5) | 16.8 (13.6–23.2) | 18.4 (15.6–32.9) |
| PP | 23.0 (16.6–32.9 ) | 21.9 (16.8–29.1) | 21.5 (17.6–NR) |
| Local relapse n (% PP) | NS | 11 (28) | 6 (16) |
| PFS months | |||
| ITT | 13.5 (10.2–18.8 ) | 10.1 (8.6–15.0 ) | 13.9 (10.9–17.2) |
| Median overall treatment time (range) days | NS | NS | 193 (162–220) |
Data are presented as %, n (%) or median (95% CI), unless otherwise stated. SAKK: Swiss Group for Clinical Cancer Research; EORTC: European Organisation for Cancer Research and Treatment; EPP: extrapleural pneumonectomy; pCR: pathologically complete response; PORT: post-operative radiotherapy; OS: overall survival; ITT: intention to treat; PP: per protocol; PFS: progression-free survival; Cis: cisplatin; gem: gemcitabine; pem: pemetrexed; NR: not reached; NS: not stated.